{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:50:42Z","timestamp":1781880642450,"version":"3.54.5"},"reference-count":129,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2011.0495","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T05:20:20Z","timestamp":1525238420000},"source":"Crossref","is-referenced-by-count":11,"title":["Hormonal Contraception"],"prefix":"10.3238","author":[{"given":"Inka","family":"Wiegratz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian J.","family":"Thaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2011,7,18]]},"reference":[{"key":"10.3238\/arztebl.2011.0495_ref1","unstructured":"WHO. . 4th ed. Geneva: WHO; 2009."},{"key":"10.3238\/arztebl.2011.0495_ref2","doi-asserted-by":"crossref","unstructured":"Kuhl H: Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005; 8(Suppl1): 3\u201363.","DOI":"10.1080\/13697130500148875"},{"key":"10.3238\/arztebl.2011.0495_ref3","doi-asserted-by":"crossref","unstructured":"Dinger J, Minh TD, Buttmann N, Bardenheuer K: Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol 2011; 117: 33\u201340.","DOI":"10.1097\/AOG.0b013e31820095a2"},{"key":"10.3238\/arztebl.2011.0495_ref4","doi-asserted-by":"crossref","unstructured":"Rosenberg M, Waugh MS: Causes and consequences of oral contraceptive noncompliance. Am J Obstet Gynecol 1999; 180: 276\u20139.","DOI":"10.1016\/S0002-9378(99)70718-0"},{"key":"10.3238\/arztebl.2011.0495_ref5","doi-asserted-by":"crossref","unstructured":"Mansour D, Inki P, Gemzell-Danielson K: Efficacy of contraceptive methods: a review of the literature. Eur J Contracept Reprod Health Care 2010; 15: 4\u201316.","DOI":"10.3109\/13625180903427675"},{"key":"10.3238\/arztebl.2011.0495_ref6","doi-asserted-by":"crossref","unstructured":"Guilbert E, Black A, Dunn S, et al.: Missed hormonal contraceptives: new recommendations. J Obstet Gynaecol Can 2008; 30: 1050\u201362.","DOI":"10.1016\/S1701-2163(16)33001-8"},{"key":"10.3238\/arztebl.2011.0495_ref7","doi-asserted-by":"crossref","unstructured":"Wiegratz I, Kuhl H: Long-cycle treatment with oral contraceptives. Drugs 2004; 64: 2447\u201362.","DOI":"10.2165\/00003495-200464210-00006"},{"key":"10.3238\/arztebl.2011.0495_ref8","doi-asserted-by":"crossref","unstructured":"Contin M, Albani F, Ambrosetto G, et al.: Variation in lamotrigine plasma concentrations with hormonal contraceptive monthly cycles in patients with epilepsy. Epilepsia 2006; 47: 1573\u20135.","DOI":"10.1111\/j.1528-1167.2006.00558.x"},{"key":"10.3238\/arztebl.2011.0495_ref9","doi-asserted-by":"crossref","unstructured":"ESHRE Capri Workshop Group: Female contraception over 40. Hum Reprod Update 2009; 15: 265\u201377.","DOI":"10.1093\/humupd\/dmp003"},{"key":"10.3238\/arztebl.2011.0495_ref10","doi-asserted-by":"crossref","unstructured":"Heinemann LAJ, Dinger JC: Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007; 75: 328\u201336.","DOI":"10.1016\/j.contraception.2006.12.018"},{"key":"10.3238\/arztebl.2011.0495_ref11","doi-asserted-by":"crossref","unstructured":"Lidegaard O, Lokkegaard E, Svendsen AL, Agger C: Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339: b2890.","DOI":"10.1136\/bmj.b2890"},{"key":"10.3238\/arztebl.2011.0495_ref12","doi-asserted-by":"crossref","unstructured":"Emmerich J, Rosendaal FR, Cattaneo M, et al.: Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism \u2013 pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86: 809\u201316.","DOI":"10.1055\/s-0037-1616136"},{"key":"10.3238\/arztebl.2011.0495_ref13","doi-asserted-by":"crossref","unstructured":"Hannaford PC: Epidemiology of the contraceptive pill and venous thromboembolism. Thromb Res 2011; 127(Suppl 3): 30\u201334.","DOI":"10.1016\/S0049-3848(11)70009-3"},{"key":"10.3238\/arztebl.2011.0495_ref14","doi-asserted-by":"crossref","unstructured":"Farley TM, Collins J, Schlesselman JJ: Hormonal contraception and risk of cardiovascular disease. An international perspective. Contraception 1998; 57: 211\u201330.","DOI":"10.1016\/S0010-7824(98)00019-5"},{"key":"10.3238\/arztebl.2011.0495_ref15","doi-asserted-by":"crossref","unstructured":"Etminan M, Takkouche B, Isorna FC, Samii A: Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 2005; 330: 63.","DOI":"10.1136\/bmj.38302.504063.8F"},{"key":"10.3238\/arztebl.2011.0495_ref16","doi-asserted-by":"crossref","unstructured":"La Vecchia C, Bosetti C: Oral contraceptives and neoplasms other than breast and female genital tract. Eur J Cancer Prev 2009; 18: 407\u201311.","DOI":"10.1097\/CEJ.0b013e32832caaca"},{"key":"10.3238\/arztebl.2011.0495_ref17","doi-asserted-by":"crossref","unstructured":"Hannaford PC, Selvaraj S, Elliott A, Angus V, Iversen L, Lee AJ: Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioners\u2019 oral contraception study. BMJ 2007; 335: 651.","DOI":"10.1136\/bmj.39289.649410.55"},{"key":"10.3238\/arztebl.2011.0495_ref18","doi-asserted-by":"crossref","unstructured":"Vessey M, Painter R: Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer 2006; 95: 385\u20139.","DOI":"10.1038\/sj.bjc.6603260"},{"key":"10.3238\/arztebl.2011.0495_ref19","doi-asserted-by":"crossref","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713\u201327.","DOI":"10.1016\/S0140-6736(96)90806-5"},{"key":"10.3238\/arztebl.2011.0495_ref20","doi-asserted-by":"crossref","unstructured":"Cibula D, Gompel A, Mueck AO, et al.: Hormonal contraception and risk of cancer. Hum Reprod Update 2010; 16: 631\u201350.","DOI":"10.1093\/humupd\/dmq022"},{"key":"10.3238\/arztebl.2011.0495_ref21","doi-asserted-by":"crossref","unstructured":"Collaborative Group on Epidemiological Studies of Ovarian Cancer: Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371: 303\u201314.","DOI":"10.1016\/S0140-6736(08)60167-1"},{"key":"10.3238\/arztebl.2011.0495_ref22","doi-asserted-by":"crossref","unstructured":"Vessey M, Yeates D, Flynn S: Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. Contraception 2010; 82: 221\u20139.","DOI":"10.1016\/j.contraception.2010.04.006"},{"key":"10.3238\/arztebl.2011.0495_ref23","doi-asserted-by":"crossref","unstructured":"Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ: Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners\u2019 Oral Contraception Study. BMJ 2010; 340: c927. doi:10.1136\/bmj.c927.","DOI":"10.1136\/bmj.c927"},{"key":"10.3238\/arztebl.2011.0495_ref24","unstructured":"Wiegratz I, Kuhl H: Langzyklus. Stuttgart: Thieme 2010; 1\u201376."},{"key":"10.3238\/arztebl.2011.0495_ref25","doi-asserted-by":"crossref","unstructured":"Piaggio G, Kapp N, von Hertzen H: Effect on pregnancy rates of the delay in the administration of levonorgestrel for emergency contraception: a combined analysis of four WHO trials. Contraception 2011, article in press.","DOI":"10.1016\/j.contraception.2010.11.010"},{"key":"10.3238\/arztebl.2011.0495_ref26","doi-asserted-by":"crossref","unstructured":"Skouby SO: Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. Eur J Contracept Reprod Health Care 2010; 15(Suppl 2): 42\u201353.","DOI":"10.3109\/13625187.2010.533002"},{"key":"10.3238\/arztebl.2011.0495_ref27","unstructured":"Kuhl H, Jung-Hoffmann C: Kontrazeption. Stuttgart: Thieme 1999; 16\u2013171."},{"key":"10.3238\/arztebl.2011.0495_ref28","unstructured":"Speroff L, Fritz MA: Oral contraception. In: Speroff L, Fritz MA (Hrsg): Clinical gynecologic endocrinology and infertility; seventh edition. Philadelphia: Lippincott Williams and Wilkins 2005; 861\u2013942."},{"key":"10.3238\/arztebl.2011.0495_ref29","doi-asserted-by":"crossref","unstructured":"Wiegratz I: Hormonale Kontrazeption. In: Leidenberger F, Strowitzki T, Ortmann O (Hrsg): Klinische Endokrinologie f\u00fcr Frauen\u00e4rzte; 4. Aufl. Heidelberg: Springer 2009; 251\u2013301.","DOI":"10.1007\/978-3-540-89760-6_11"},{"key":"10.3238\/arztebl.2011.0495_ref30","unstructured":"Pearl R: Contraception and fertility in 2,000 women. Hum Biol 1932; 4: 363\u2013407."},{"key":"10.3238\/arztebl.2011.0495_ref31","doi-asserted-by":"crossref","unstructured":"Dinger JC, Cronin M, M\u00f6hner S, Schellschmidt I, Minh TD, Westhoff C: Oral contraceptive effectiveness according to body mass index, weight, age, and other factors. Am J Obstet Gynecol 2009; 201: 263.e1\u20139.","DOI":"10.1016\/j.ajog.2009.03.017"},{"key":"10.3238\/arztebl.2011.0495_ref32","doi-asserted-by":"crossref","unstructured":"Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit (FFPRHC). Faculty statement from the CEU on a new publication: WHO selected practice recommendations for contraceptive use update. Missed pills: new recommendations. J Fam Plann Reprod Health Care 2005; 31: 153\u20135.","DOI":"10.1783\/1471189053629572"},{"key":"10.3238\/arztebl.2011.0495_ref33","doi-asserted-by":"crossref","unstructured":"Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF: 20 \u00b5g versus >20 \u00b5g estrogen combined oral contraceptives for contraception . Cochrane Database Syst Rev 2011; 1: CD003989.","DOI":"10.1002\/14651858.CD003989.pub4"},{"key":"10.3238\/arztebl.2011.0495_ref34","doi-asserted-by":"crossref","unstructured":"Wiegratz I, Hommel HH, Zimmermann T, Kuhl K: Attitude of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contaception 2004; 69: 37\u201342.","DOI":"10.1016\/j.contraception.2003.09.004"},{"key":"10.3238\/arztebl.2011.0495_ref35","doi-asserted-by":"crossref","unstructured":"Dickinson BD, Altman RD, Nielsen NH, Sterling ML: Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol 2001; 98: 853\u201360.","DOI":"10.1016\/S0029-7844(01)01532-0"},{"key":"10.3238\/arztebl.2011.0495_ref36","doi-asserted-by":"crossref","unstructured":"Toh S, Mitchell AA, Anderka M, de Jong-van den Berg LTW, Hernandez-Diaz S: Antibiotics and oral contraceptive failure \u2013 a case cross-over study. Contraception 2011; 83: 418\u201325.","DOI":"10.1016\/j.contraception.2010.08.020"},{"key":"10.3238\/arztebl.2011.0495_ref37","doi-asserted-by":"crossref","unstructured":"Christensen J, Petrenaite V, Atterman, J et al.: Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia 2007; 48: 484\u20139.","DOI":"10.1111\/j.1528-1167.2007.00997.x"},{"key":"10.3238\/arztebl.2011.0495_ref38","doi-asserted-by":"crossref","unstructured":"The American College of Obstetrics and Gynecologists: Noncontraceptive uses of hormonal contraceptives. Practice Bulletin No 110. Obstet Gynecol 2010; 115: 206\u201318.","DOI":"10.1097\/AOG.0b013e3181cb50b5"},{"key":"10.3238\/arztebl.2011.0495_ref39","doi-asserted-by":"crossref","unstructured":"Redmond G, Godwin AJ, Olson W, Lippman J: Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence. Contraception 1999; 60: 81\u20135.","DOI":"10.1016\/S0010-7824(99)00069-4"},{"key":"10.3238\/arztebl.2011.0495_ref40","doi-asserted-by":"crossref","unstructured":"Aznar-Ramos R, Ginger-Velazquez J, Lara-Ricalde R, Martinez-Manautou J: Incidence of side effects with contraceptive placebo. Am J Obstet Gynecol 1969; 105: 1144\u20139.","DOI":"10.1016\/0002-9378(69)90142-2"},{"key":"10.3238\/arztebl.2011.0495_ref41","doi-asserted-by":"crossref","unstructured":"Goldzieher JW, Moses LE, Averkin E, Scheel C, Taber BZ: A placebo-controlled double-blind crossover investigation of the side effects attributed to oral contraceptives. Fertil Steril 1971; 22: 609\u201323.","DOI":"10.1016\/S0015-0282(16)38469-2"},{"key":"10.3238\/arztebl.2011.0495_ref42","doi-asserted-by":"crossref","unstructured":"Tchaikovski S, Tans G, Rosing J. Venous thrombosis and oral contraceptives: current status. Womens Health 2006; 2: 761\u201372.","DOI":"10.2217\/17455057.2.5.761"},{"key":"10.3238\/arztebl.2011.0495_ref43","doi-asserted-by":"crossref","unstructured":"Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ3rd: Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143: 697\u2013706.","DOI":"10.7326\/0003-4819-143-10-200511150-00006"},{"key":"10.3238\/arztebl.2011.0495_ref44","doi-asserted-by":"crossref","unstructured":"Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ: Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008; 6: 632\u20137.","DOI":"10.1111\/j.1538-7836.2008.02921.x"},{"key":"10.3238\/arztebl.2011.0495_ref45","doi-asserted-by":"crossref","unstructured":"Reid R, Leyland N, Wolfman W, et al.: Oral contraceptives and the risk of venous thromboembolism: an update. J Obstet Gynaecol Can 2010; 252: 1192\u20137.","DOI":"10.1016\/S1701-2163(16)34746-6"},{"key":"10.3238\/arztebl.2011.0495_ref46","doi-asserted-by":"crossref","unstructured":"Heinemann LA, Dinger JC, Assmann A, Minh TD: Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation \u201epill scare\u201c. Contraception 2010; 81: 401\u20137.","DOI":"10.1016\/j.contraception.2009.12.014"},{"key":"10.3238\/arztebl.2011.0495_ref47","doi-asserted-by":"crossref","unstructured":"Nightingale AL, Lawrenson RA, Simpson EL, Williams TJ, MacRae KD, Fermer RD: The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Health Care 2000; 5: 265\u201374.","DOI":"10.1080\/13625180008500402"},{"key":"10.3238\/arztebl.2011.0495_ref48","doi-asserted-by":"crossref","unstructured":"Pomp ER, Rosendaal FR, Doggen CJ. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol 2008; 83: 97\u2013102.","DOI":"10.1002\/ajh.21059"},{"key":"10.3238\/arztebl.2011.0495_ref49","doi-asserted-by":"crossref","unstructured":"Cole JA, Norman H, Doherty M, Walker AM: Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 2007; 109: 339\u201346.","DOI":"10.1097\/01.AOG.0000250968.82370.04"},{"key":"10.3238\/arztebl.2011.0495_ref50","doi-asserted-by":"crossref","unstructured":"Wu O, Robertson L, Langhorne P, et al.: Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 2005; 94: 17\u201325.","DOI":"10.1160\/TH04-11-0759"},{"key":"10.3238\/arztebl.2011.0495_ref51","doi-asserted-by":"crossref","unstructured":"Kaunitz AM: Hormonal contraception in women of older reproductive age. N Engl J Med 2008; 358: 1262\u201370.","DOI":"10.1056\/NEJMcp0708481"},{"key":"10.3238\/arztebl.2011.0495_ref52","doi-asserted-by":"crossref","unstructured":"Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ 1996; 313: 1127\u201330.","DOI":"10.1136\/bmj.313.7065.1127"},{"key":"10.3238\/arztebl.2011.0495_ref53","doi-asserted-by":"crossref","unstructured":"Gomes MPV, Deitcher SR: Risk of venous thromboembolic di-sease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 2004; 164: 1965\u201376.","DOI":"10.1001\/archinte.164.18.1965"},{"key":"10.3238\/arztebl.2011.0495_ref54","doi-asserted-by":"crossref","unstructured":"Baillargeon JP, McClish DK, Essah PA, Nestler JE: Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 2005; 90: 3863\u201370.","DOI":"10.1210\/jc.2004-1958"},{"key":"10.3238\/arztebl.2011.0495_ref55","doi-asserted-by":"crossref","unstructured":"Chakhtoura Z, Canonico M, Gompel A, Scarabin PY, Plu-Bureau G: Progestogen-only contraceptives and the risk of acute myocardial infarction: a meta-analysis. J Clin Endocrinol Metab 2011; 96: 1169\u201374.","DOI":"10.1210\/jc.2010-2065"},{"key":"10.3238\/arztebl.2011.0495_ref56","doi-asserted-by":"crossref","unstructured":"Tzourio C, Tehindrazanarivelo A, Iglesias S, et al.: Case-control study of migraine and risk of ischaemic stroke in young women. BMJ 1995; 310: 830\u20133.","DOI":"10.1136\/bmj.310.6983.830"},{"key":"10.3238\/arztebl.2011.0495_ref57","doi-asserted-by":"crossref","unstructured":"Kruit MC, van Buchem MA, Hofman PA, et al.: Migraine as a risk factor for subclinical brain lesions. JAMA 2004; 291: 427\u201334.","DOI":"10.1001\/jama.291.4.427"},{"key":"10.3238\/arztebl.2011.0495_ref58","doi-asserted-by":"crossref","unstructured":"MacClellan LR, Giles W, Cole J, et al.: Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study. Stroke 2007; 38: 2438\u201345.","DOI":"10.1161\/STROKEAHA.107.488395"},{"key":"10.3238\/arztebl.2011.0495_ref59","doi-asserted-by":"crossref","unstructured":"Maillette de Buy Wenninger L, Terpstra V, Beuers U: Focal nodular hyperplasia and hepatic adenoma: epidemiology and pathology. Dig Surg 2010; 27: 24\u201331.","DOI":"10.1159\/000268404"},{"key":"10.3238\/arztebl.2011.0495_ref60","doi-asserted-by":"crossref","unstructured":"Karhunen PJ: Benign hepatic tumours and tumour-like conditions in men. J Clin Pathol 1986; 39: 183\u20138.","DOI":"10.1136\/jcp.39.2.183"},{"key":"10.3238\/arztebl.2011.0495_ref61","doi-asserted-by":"crossref","unstructured":"Wanless IR: Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular no-dules. Hepatology 1990; 11: 787\u201397.","DOI":"10.1002\/hep.1840110512"},{"key":"10.3238\/arztebl.2011.0495_ref62","doi-asserted-by":"crossref","unstructured":"Scalori A, Tavani A, Gallus S, La Vecchia C, Colombo M: Oral contraceptives and the risk of focal nodular hyperplasia of the liver: a case-control study. Am J Obstet Gynecol 2002; 186: 195\u20137.","DOI":"10.1067\/mob.2002.120277"},{"key":"10.3238\/arztebl.2011.0495_ref63","doi-asserted-by":"crossref","unstructured":"Mathieu D, Kobeiter H, Cherqui D, Rahmoundi A, Dhumeaux D: Oral contraceptive intake in women with focal nodular hyperplasia of the liver Lancet 1998; 352: 1679\u201380.","DOI":"10.1016\/S0140-6736(05)61451-1"},{"key":"10.3238\/arztebl.2011.0495_ref64","doi-asserted-by":"crossref","unstructured":"Farges O, Ferreira N, Dokmak S, Belghiti J, Bedossa P, Paradis V: Changing trends in malignant transformation of hepatocellular adenoma. Gut 2011; 60: 85\u20139.","DOI":"10.1136\/gut.2010.222109"},{"key":"10.3238\/arztebl.2011.0495_ref65","doi-asserted-by":"crossref","unstructured":"Rooks JB, Ory HW, Ishak KG, et al.: Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 1979; 242; 644\u20138.","DOI":"10.1001\/jama.242.7.644"},{"key":"10.3238\/arztebl.2011.0495_ref66","doi-asserted-by":"crossref","unstructured":"Heinemann LA, Weimann A, Gerken G, Thiel C, Schlaud M, DoMinh T: Modern oral contraceptive use and benign liver tumors: the German Benign Liver Tumor Case-Control Study. Eur J Contracept Reprod Health Care 1998; 3: 194\u2013200.","DOI":"10.3109\/13625189809167253"},{"key":"10.3238\/arztebl.2011.0495_ref67","doi-asserted-by":"crossref","unstructured":"Wingo PA, Austin H, Marchbanks PA, et al.: Oral contraceptives and the risk of death from breast cancer. Obstet Gynecol 2007; 110: 793\u2013800.","DOI":"10.1097\/01.AOG.0000284446.22251.6e"},{"key":"10.3238\/arztebl.2011.0495_ref68","doi-asserted-by":"crossref","unstructured":"Hankinson SE, Colditz GA, Manson JE, et al.: A prospective study of oral contraceptive use and risk of breast cancer (Nurses\u2018 Health Study, United States). Cancer Causes Control 1997; 8: 65\u201372.","DOI":"10.1023\/A:1018435205695"},{"key":"10.3238\/arztebl.2011.0495_ref69","doi-asserted-by":"crossref","unstructured":"Marchbanks PA, McDonald JA, Wilson HG, et al.: Oral contraceptives and the risk of breast cancer. N Engl J Med 2002; 346: 2025\u201332.","DOI":"10.1056\/NEJMoa013202"},{"key":"10.3238\/arztebl.2011.0495_ref70","unstructured":"Kumle M, Weiderpass E, Braaten T, Persson I, Adami HO, Lund E: Use of oral contraceptives and breast cancer risk: The Norwe-gian-Swedish Women\u2019s Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev 2002; 11: 1375\u201381."},{"key":"10.3238\/arztebl.2011.0495_ref71","doi-asserted-by":"crossref","unstructured":"Kahlenborn C, Modugno F, Potter DM, Severs WB: Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin Proc 2006; 81: 1290\u2013302.","DOI":"10.4065\/81.10.1290"},{"key":"10.3238\/arztebl.2011.0495_ref72","doi-asserted-by":"crossref","unstructured":"Iodice S, Barile M, Rotmensz N, et al.: Oral contraceptive use and breast or ovarian cancer risk in BRCA1\/2 carriers: a meta-analysis. Eur J Cancer 2010; 46: 2275\u201384.","DOI":"10.1016\/j.ejca.2010.04.018"},{"key":"10.3238\/arztebl.2011.0495_ref73","doi-asserted-by":"crossref","unstructured":"Gaffield ME, Culwell KR, Ravi A: Oral contraceptives and family history of breast cancer. Contraception 2009; 80: 372\u201380.","DOI":"10.1016\/j.contraception.2009.04.010"},{"key":"10.3238\/arztebl.2011.0495_ref74","doi-asserted-by":"crossref","unstructured":"McNaught J, Reid RL, SOGC\/GOC Joint Ad Hoc Committee on Breast Cancer, et al.: Progesterone-only and non-hormonal contraception in the breast cancer survivor: Joint review and committee opinion of the Society of Obstetricians and Gynaecologists of Canada and the Society of Gynecologic Oncologists of Canada. J Obstet Gynaecol Can 2006; 28: 616\u201339.","DOI":"10.1016\/S1701-2163(16)32195-8"},{"key":"10.3238\/arztebl.2011.0495_ref75","doi-asserted-by":"crossref","unstructured":"La Vecchia C, Bosetti C: Benefits and risks of oral contraceptives on cancer. Eur J Cancer Prev 2004; 13: 467\u201370.","DOI":"10.1097\/00008469-200412000-00001"},{"key":"10.3238\/arztebl.2011.0495_ref76","doi-asserted-by":"crossref","unstructured":"La Vecchia C. Oral contraceptives and ovarian cancer: an update, 1998-2004. Eur J Cancer Prev 2006; 15: 117\u201324.","DOI":"10.1097\/01.cej.0000179274.24200.9d"},{"key":"10.3238\/arztebl.2011.0495_ref77","unstructured":"International Agency for Research on Cancer (IARC): Monographs on the Evaluations of Carcinogenic risks to humans. Combined estrogen-progestogen contraceptives and combined estrogen-progestin menopausal therapy. Vol 91 (2007),"},{"key":"10.3238\/arztebl.2011.0495_ref78","doi-asserted-by":"crossref","unstructured":"Moreno V, Bosch FX, Munoz N, et al.: Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002; 359: 1085\u201392.","DOI":"10.1016\/S0140-6736(02)08150-3"},{"key":"10.3238\/arztebl.2011.0495_ref79","doi-asserted-by":"crossref","unstructured":"Bosetti C, Bravi F, Negri E, La Vecchia C: Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis. Hum Reprod Update 2009; 15: 489\u201398.","DOI":"10.1093\/humupd\/dmp017"},{"key":"10.3238\/arztebl.2011.0495_ref80","doi-asserted-by":"crossref","unstructured":"Fernandez E, La Vecchia C, Balducci A, Chatenoud L, Franceschi S, Negri E: Oral contraceptives and colorectal cancer risk: a meta-analysis. Br J Cancer 2001; 84: 722\u20137.","DOI":"10.1054\/bjoc.2000.1622"},{"key":"10.3238\/arztebl.2011.0495_ref81","doi-asserted-by":"crossref","unstructured":"Maheshwari S, Sarraj A, Kramer J, El-Serag HB: Oral contracep-tion and the risk of hepatocellular carcinoma. J Hepatol 2007; 47: 506\u201313.","DOI":"10.1016\/j.jhep.2007.03.015"},{"key":"10.3238\/arztebl.2011.0495_ref82","doi-asserted-by":"crossref","unstructured":"Vessey M, Painter R, Yeates D: Mortality in relation to oral contraceptive use and cigarette smoking. Lancet 2003; 362: 185\u201391.","DOI":"10.1016\/S0140-6736(03)13907-4"},{"key":"10.3238\/arztebl.2011.0495_ref83","doi-asserted-by":"crossref","unstructured":"Meinhold CL, Berrington de Gonzales A, Bowman ED, et al.: Reproductive and hormonal factors and the risk of nonsmall cell lung cancer. Int J Cancer 2011: 128; 1404\u201313.","DOI":"10.1002\/ijc.25434"},{"key":"10.3238\/arztebl.2011.0495_ref84","doi-asserted-by":"crossref","unstructured":"Burkman RT, Collins JA, Shulman LP, Williams JK: Current perspectives on oral contraceptive use. Am J Obstet Gynecol 2001; 185: 4\u201312.","DOI":"10.1067\/mob.2001.117416"},{"key":"10.3238\/arztebl.2011.0495_ref85","doi-asserted-by":"crossref","unstructured":"Petitti DB: Combination estrogen-progestin oral contraceptives. N Engl J Med 2003; 349: 1443\u201350.","DOI":"10.1056\/NEJMcp030751"},{"key":"10.3238\/arztebl.2011.0495_ref86","doi-asserted-by":"crossref","unstructured":"ESHRE Capri Workshop Group: Noncontraceptive health benefits of combined oral contraception. Hum Reprod Update 2005; 11: 513\u201325.","DOI":"10.1093\/humupd\/dmi019"},{"key":"10.3238\/arztebl.2011.0495_ref87","doi-asserted-by":"crossref","unstructured":"Jamieson DJ, Steege JF: The prevalence of dysmenorrhea, dyspareunia, pelvic pain, and irritable bowel syndrome in primary care practices. Obstet Gynecol 1996; 87: 55\u20138.","DOI":"10.1016\/0029-7844(95)00360-6"},{"key":"10.3238\/arztebl.2011.0495_ref88","doi-asserted-by":"crossref","unstructured":"Milsom I, Lete I, Bjertnaes A, et al.: Effects on cycle control and body weight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 \u00b5g ethinyl estradiol and 3 mg drospirenone. Hum Reprod 2006; 21: 2304\u201311.","DOI":"10.1093\/humrep\/del162"},{"key":"10.3238\/arztebl.2011.0495_ref89","doi-asserted-by":"crossref","unstructured":"Hendrix SL, Alexander NJ: Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive. Contraception 2002; 66: 393\u20139.","DOI":"10.1016\/S0010-7824(02)00414-6"},{"key":"10.3238\/arztebl.2011.0495_ref90","doi-asserted-by":"crossref","unstructured":"Winkler UH, Ferguson H, Mulders JA: Cycle control, quality of life, and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. Contraception 2004; 69: 469\u201376.","DOI":"10.1016\/j.contraception.2003.12.017"},{"key":"10.3238\/arztebl.2011.0495_ref91","doi-asserted-by":"crossref","unstructured":"Milsom I, Sundell G, Andersch B: The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea. Contraception 1990: 42; 497\u2013506.","DOI":"10.1016\/0010-7824(90)90078-A"},{"key":"10.3238\/arztebl.2011.0495_ref92","doi-asserted-by":"crossref","unstructured":"Hohmann H, Creinin MD: The contraceptive implant. Clin Obstet Gynecol 2007; 50: 907\u201317.","DOI":"10.1097\/GRF.0b013e318159c2f6"},{"key":"10.3238\/arztebl.2011.0495_ref93","doi-asserted-by":"crossref","unstructured":"Funk S, Miller MM, Mishell DR Jr, et al.: Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception 2005; 71: 319\u201326.","DOI":"10.1016\/j.contraception.2004.11.007"},{"key":"10.3238\/arztebl.2011.0495_ref94","doi-asserted-by":"crossref","unstructured":"Croxatto HB. Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care 2000; 5(Suppl 2): 21\u20138.","DOI":"10.1080\/14730782.2000.12288982"},{"key":"10.3238\/arztebl.2011.0495_ref95","doi-asserted-by":"crossref","unstructured":"Varma R, Sinha D, Grupta JK: Non-contraceptive uses of levonorgestrel-releasing hormone-system (LNG-IUS)\u2014a systematic enquiry and overview. Eur J Obstet Gynecol Reprod Biol 2006; 125: 9\u201328.","DOI":"10.1016\/j.ejogrb.2005.10.029"},{"key":"10.3238\/arztebl.2011.0495_ref96","doi-asserted-by":"crossref","unstructured":"Rodriguez MI, Darney PD: Non-contraceptive applications of the levonorgestrel intrauterine system. Int J Womens Health 2010; 2: 63\u20138.","DOI":"10.2147\/IJWH.S6344"},{"key":"10.3238\/arztebl.2011.0495_ref97","doi-asserted-by":"crossref","unstructured":"Vercellini P, Somigliana E, Vigan\u00f2 P, Abbiati A, Barbara G, Crosignani PG. Endometriosis: current therapies and new pharmacological developments. Drugs 2009; 69: 649\u201375.","DOI":"10.2165\/00003495-200969060-00002"},{"key":"10.3238\/arztebl.2011.0495_ref98","doi-asserted-by":"crossref","unstructured":"Maia HJ, Casoy J: Non-contraceptive health benefits of oral contraceptives. Eur J Contracept Reprod Health Care 2008; 13: 17\u201324.","DOI":"10.1080\/13625180701712745"},{"key":"10.3238\/arztebl.2011.0495_ref99","unstructured":"Deutsche Gesellschaft f\u00fcr Gyn\u00e4kologie und Geburtshilfe e. V. (DGGG): Aktuelle Leitlinien, Diagnostik und Therapie der Endometriose (S1) 2010;"},{"key":"10.3238\/arztebl.2011.0495_ref100","doi-asserted-by":"crossref","unstructured":"Parazzini F, Negri E, La Vecchia C, Fedele L, Rabaiotti M, Luchini L: Oral contraceptive use and risk of uterine fibroids. Obstet Gynecol 1992; 79: 430\u20133.","DOI":"10.1097\/00006250-199203000-00021"},{"key":"10.3238\/arztebl.2011.0495_ref101","doi-asserted-by":"crossref","unstructured":"Ross RK, Pike MC, Vessey MP, Bull D, Yeates D, Casagrande JT: Risk factors for uterine fibroids: reduced risk association with oral contraceptives. Br Med J (Clin Res Ed) 1986; 293: 359\u201362.","DOI":"10.1136\/bmj.293.6543.359"},{"key":"10.3238\/arztebl.2011.0495_ref102","doi-asserted-by":"crossref","unstructured":"Friedman AJ, Thomas PP: Does low-dose combination oral contraceptive use affect uterine size or menstrual flow in premenopausal women with leiomyomas? Obstet Gynecol 1995; 85: 631\u20135.","DOI":"10.1016\/0029-7844(95)00007-E"},{"key":"10.3238\/arztebl.2011.0495_ref103","doi-asserted-by":"crossref","unstructured":"Chiaffarino F, Parazzini F, La Vecchia C, Marsico S, Surace M, Ricci E: Use of oral contraceptives and uterine fibroids: results from a case-control study. Br J Obstet Gynaecol 1999; 106: 857\u201360.","DOI":"10.1111\/j.1471-0528.1999.tb08409.x"},{"key":"10.3238\/arztebl.2011.0495_ref104","doi-asserted-by":"crossref","unstructured":"Wise LA, Palmer JR, Harlow BL, et al.: Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol 2004; 159: 113\u201323.","DOI":"10.1093\/aje\/kwh016"},{"key":"10.3238\/arztebl.2011.0495_ref105","doi-asserted-by":"crossref","unstructured":"Marshall LM, Spiegelman D, Goldman MB, et al.: A prospective study of reproductive factors and oral contraceptive use in rela-tion to the risk of uterine leiomyomata. Fertil Steril 1998; 70: 432\u20139.","DOI":"10.1016\/S0015-0282(98)00208-8"},{"key":"10.3238\/arztebl.2011.0495_ref106","doi-asserted-by":"crossref","unstructured":"Grady-Weliky TA: Premenstrual dysphoric disorder. N Engl J Med 2003; 348: 433\u20138.","DOI":"10.1056\/NEJMcp012067"},{"key":"10.3238\/arztebl.2011.0495_ref107","doi-asserted-by":"crossref","unstructured":"Coffee AL, Kuehl TJ, Willis S, Sulak PJ. Oral contraceptives and premenstrual symptoms: comparison of a 21\/7 and extended regimen. Am J Obstet Gynecol 2006; 195: 1311\u20139.","DOI":"10.1016\/j.ajog.2006.05.012"},{"key":"10.3238\/arztebl.2011.0495_ref108","doi-asserted-by":"crossref","unstructured":"Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A: Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005; 106: 492\u2013501.","DOI":"10.1097\/01.AOG.0000175834.77215.2e"},{"key":"10.3238\/arztebl.2011.0495_ref109","doi-asserted-by":"crossref","unstructured":"Faculty of Family Planning and Reproductive Health Care: FFPRHC Guidance (January 2005) contraception for women aged over 40 years. J Fam Plann Reprod Health Care 2005; 31: 51\u201363.","DOI":"10.1783\/0000000052973086"},{"key":"10.3238\/arztebl.2011.0495_ref110","doi-asserted-by":"crossref","unstructured":"Gebbie AE, Hardman SM: Contraception in the perimenopause \u2013 old and new. Menopause Int 2010; 16: 33\u20137.","DOI":"10.1258\/mi.2010.010013"},{"key":"10.3238\/arztebl.2011.0495_ref111","doi-asserted-by":"crossref","unstructured":"Wiegratz I, Mittmann K, Dietrich H, Zimmermann T, Kuhl H: Fertility after discontinuation of treatment with an oral contraceptive containing 30 mcg of ethinyl estradiol and 2 mg of dienogest. Fertil Steril 2006; 85: 1812\u20139.","DOI":"10.1016\/j.fertnstert.2005.11.052"},{"key":"10.3238\/arztebl.2011.0495_ref112","doi-asserted-by":"crossref","unstructured":"Ahrendt HJ, Makalova D, Parke S, Mellinger U, Mansour D: Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate\/dienogest and ethinylestradiol\/levonorgestrel. Contraception 2009; 80: 436\u201344.","DOI":"10.1016\/j.contraception.2009.03.018"},{"key":"10.3238\/arztebl.2011.0495_ref113","doi-asserted-by":"crossref","unstructured":"Palacios S, Wildt L, Parke S, Machlitt A, R\u00f6mer T, Bitzer J: Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate\/dienogest): a phase III trial. Eur J Obstet Gynecol Reprod Biol 2010; 149: 57\u201362.","DOI":"10.1016\/j.ejogrb.2009.11.001"},{"key":"10.3238\/arztebl.2011.0495_ref114","doi-asserted-by":"crossref","unstructured":"Endrikat J, Parke S, Trummer D, Schmidt W, Duijkers I Klipping C: Ovulation inhibition with four variations of a four-phasic estradiol valerate\/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception 2008; 78: 218\u201325.","DOI":"10.1016\/j.contraception.2008.05.004"},{"key":"10.3238\/arztebl.2011.0495_ref115","unstructured":"Bundeszentrale f\u00fcr gesundheitliche Aufkl\u00e4rung (BZGA): Verh\u00fctungsverhalten Erwachsener. Ergebnisse der Repr\u00e4sentativbefragung 2007;"},{"key":"10.3238\/arztebl.2011.0495_ref116","unstructured":"European network of population-based registries for the epidemiologic surveillance of congenital anomalies (EUROCAT): ; Prevalence Tables; Daten von 2005\u20132009."},{"key":"10.3238\/arztebl.2011.0495_ref117","unstructured":"Ri\u00dfmann A, Hoyer-Schuschke J, K\u00f6hn A, Vogt C, G\u00f6tz D: Jahresbericht des Bundeslandes Sachsen-Anhalt zur H\u00e4ufigkeit von congenitalen Fehlbildungen und Anomalien sowie genetisch bedingten Erkrankungen 2009: ."},{"key":"10.3238\/arztebl.2011.0495_ref118","unstructured":"Taylor T, Farkouh R, Graham J, et al.: Potential impact of using folate-fortified oral contraceptives on risk reduction in neural tube defects in the United States and Germany. Eur J Contracept Reprod Health Care 2010; 15(Suppl.1): 128\u20139."},{"key":"10.3238\/arztebl.2011.0495_ref119","doi-asserted-by":"crossref","unstructured":"Piaggio G, von Hertzen H, Grimes DA, Van Look PF, on behalf of the Task Force on Postovulatory Methods of Fertility Regulation: Timing of emergency contraception with levonorgestrel or the Yuzpe regimen. Lancet 1999; 353: 721.","DOI":"10.1016\/S0140-6736(98)05718-3"},{"key":"10.3238\/arztebl.2011.0495_ref120","doi-asserted-by":"crossref","unstructured":"Von Hertzen H, Piaggio G, Van Look PF: Emergency contraception with levonorgestrel or the Yuzpe regimen. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 1998; 352: 1939.","DOI":"10.1016\/S0140-6736(05)60440-0"},{"key":"10.3238\/arztebl.2011.0495_ref121","doi-asserted-by":"crossref","unstructured":"Von Hertzen HG, Piaggio G, Ding J, et al.: Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002; 360: 1803\u201310.","DOI":"10.1016\/S0140-6736(02)11767-3"},{"key":"10.3238\/arztebl.2011.0495_ref122","doi-asserted-by":"crossref","unstructured":"Ho PC, Kwan MS: A prospective randomized comparison of levonorgestrel with the Yuzpe regimen in post-coital contraception. Hum Reprod 1993; 8: 389\u201392.","DOI":"10.1093\/oxfordjournals.humrep.a138057"},{"key":"10.3238\/arztebl.2011.0495_ref123","doi-asserted-by":"crossref","unstructured":"Lalitkumar PG, Lalitkumar S, Meng CX, et al.: Mifepristone, but not levonorgestrel, inhibits human blastocyst attachment to an in vitro endometrial three-dimensional cell culture model. Hum Reprod 2007; 22: 3031\u20137.","DOI":"10.1093\/humrep\/dem297"},{"key":"10.3238\/arztebl.2011.0495_ref124","doi-asserted-by":"crossref","unstructured":"Meng CX, Andersson KL, Bentin-Ley U, Gemzell-Danielsson K, Lalitkumar PG: Effect of levonorgestrel and mifepristone on endometrial receptivity markers in a three-dimensional human cell culture model. Fertil Steril 2009; 91: 256\u201364.","DOI":"10.1016\/j.fertnstert.2007.11.007"},{"key":"10.3238\/arztebl.2011.0495_ref125","doi-asserted-by":"crossref","unstructured":"Zhang L, Chen J, Wang Y, Ren F, Yu W, Cheng L: Pregnancy outcome after levonorgestrel-only emergency contraception failure: a prospective cohort study. Hum Reprod 2009; 24: 1605\u201311.","DOI":"10.1093\/humrep\/dep076"},{"key":"10.3238\/arztebl.2011.0495_ref126","doi-asserted-by":"crossref","unstructured":"Creinin MD, Schlaff W, Archer DF, et al.: Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol 2006; 108: 1089\u201397.","DOI":"10.1097\/01.AOG.0000239440.02284.45"},{"key":"10.3238\/arztebl.2011.0495_ref127","doi-asserted-by":"crossref","unstructured":"Glasier AF, Cameron ST, Fine PM, et al.: Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet 2010; 375: 555\u201362.","DOI":"10.1016\/S0140-6736(10)60101-8"},{"key":"10.3238\/arztebl.2011.0495_ref128","doi-asserted-by":"crossref","unstructured":"Cheng L, G\u00fclmezoglu AM, Piaggio G, Ezcurra E, Van Look PF: Interventions for emergency contraception. Cochrane Database Syst Rev 2008; 2: CD001324.","DOI":"10.1002\/14651858.CD001324.pub3"},{"key":"10.3238\/arztebl.2011.0495_ref129","doi-asserted-by":"crossref","unstructured":"Bastianelli C, Farris M, Benagiano G: Emergency contraception: a review. Eur J Contracept Reprod Health Care 2008; 13: 9\u201316.","DOI":"10.1080\/13625180701781096"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2011.0495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T06:57:20Z","timestamp":1693637840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2011.0495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,18]]},"references-count":129,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2011.0495","relation":{"is-cited-by":[{"id-type":"doi","id":"10.1007\/s00198-017-4036-x","asserted-by":"object"},{"id-type":"doi","id":"10.1007\/s00112-017-0349-2","asserted-by":"object"}]},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,18]]}}}